Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 15, 2018
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based ...
October 15, 2018
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
PITTSBURGH, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering ...
October 15, 2018
Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
October 15, 2018
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc, (TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, ...
October 15, 2018
Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron ...
October 15, 2018
Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
October 15, 2018
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, announced today it has signed a license agreement with Lysogene (LYS.PA) (FR0013233475 ...
October 11, 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
NANTES, France, Oct. 10, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) today announced the submission of an Investigational New Drug (IND) application ...
October 11, 2018
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
Transgene (TNG.PA), a biotech company that designs and develops virus-based immunotherapies, announces that the detailed results of the Phase 1b clinical trial using TG1050 confirm ...
October 11, 2018
Veloxis to Present at Jefferies 2018 London Healthcare Conference
Veloxis Pharmaceuticals A/S (VELO.CO) announced today that CEO Craig Collard will present at the Jefferies 2018 London Healthcare Conference at 8:00 AM GMT on Thursday, November ...
October 11, 2018
Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis
TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for ...
October 11, 2018
iCAD Announces Exceptional Study Results Demonstrating Significant Advantages of Revolutionary Artificial Intelligence Technology for Digital Breast Tomosynthesis
NASHUA, N.H. and ATHENS, Greece, Oct. 11, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today ...
October 11, 2018
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018
SALT LAKE CITY, Oct. 11, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 ...
October 11, 2018
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) --  Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced the appointment of Gil Efron as ...
October 11, 2018
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018/PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data ...
October 11, 2018
ADMA Biologics Provides Regulatory Update for BIVIGAM®
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
October 9, 2018
Check-Cap Announces IDE Submission to FDA for Its C-Scan® System
ISFIYA, Israel, Oct. 9, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW) (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, ...
October 9, 2018
SUNY Upstate Medical University Selects iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
NASHUA, N.H. and SYRACUSE, N.Y., Oct. 09, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today ...
October 9, 2018
Vermillion, Inc. Announces the Launch of OVA1®+
AUSTIN, Texas, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the launch of ...
October 9, 2018
Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the ...
Page 12 of 117